.jpg?format=webp&width=780)
From January 2005 to 2023, the average selling price of omalizumab, a medication used for asthma and chronic idiopathic urticaria, increased by almost 60%. Medicare Part B and D spending on omalizumab between 2016 and 2021 amounted to over $3.7 billion. During the same period, the utilization of omalizumab under Medicare Part B and D increased by approximately 30%. These findings highlight the significant cost and usage trends associated with omalizumab over the past decade, indicating its importance and impact on healthcare expenditures.
Like
Save
Share